Department of Pediatrics, Division of Pediatric Infectious Diseases, The Johns Hopkins University School of Medicine,; Department of Pediatrics, Division of Pediatric Infectious Diseases, University of Texas Southwestern Medical Center, Dallas, Texas.
Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health.
Open Forum Infect Dis. 2016 Jan 18;3(1):ofw006. doi: 10.1093/ofid/ofw006. eCollection 2016 Jan.
Background. Autochthonous hepatitis E virus (HEV) infection has been reported in over 200 solid organ transplant (SOT) recipients since 2006, yet little is known about the burden of HEV among SOT recipients in North America. We performed a retrospective, cross-sectional study to investigate the prevalence and risk factors associated with HEV infection among SOT recipients at our institution. Methods. Children and adults (n = 311) who received allografts between 1988 and 2012 at the Johns Hopkins Hospital were assessed for evidence of HEV infection by testing posttransplantation serum samples for HEV antibody by enzyme immunoassay and HEV RNA by reverse transcription quantitative polymerase chain reaction. Individuals with evidence of posttransplant HEV infection (presence of anti-HEV immunoglobulin [Ig]M antibody, anti-HEV IgG seroconversion, or HEV RNA) were compared with individuals without evidence of infection and assessed for risk factors associated with infection. Results. Twelve individuals (4%) developed posttransplant HEV infection. Posttransplant HEV infection was associated with an increased risk for graft rejection (odds ratio, 14.2; P = .03). No individuals developed chronic infection. Conclusions. Solid organ transplant recipients in the United States are at risk for posttransplant HEV infection. Further studies are needed to characterize environmental risk factors and the risk of HEV infection after SOT in North America.
自 2006 年以来,已有超过 200 例实体器官移植(SOT)受者报告发生了本土型戊型肝炎病毒(HEV)感染,但北美 SOT 受者中 HEV 感染的负担情况知之甚少。我们进行了一项回顾性横断面研究,以调查本机构 SOT 受者中 HEV 感染的流行率和相关风险因素。
1988 年至 2012 年期间在约翰霍普金斯医院接受同种异体移植物的儿童和成人(n=311)通过酶免疫测定检测移植后血清样本中的 HEV 抗体,以及通过逆转录定量聚合酶链反应检测 HEV RNA,评估其是否存在 HEV 感染的证据。将存在移植后 HEV 感染证据(抗 HEV 免疫球蛋白[Ig]M 抗体、抗 HEV IgG 血清转化或 HEV RNA 存在)的个体与未感染的个体进行比较,并评估与感染相关的风险因素。
12 名个体(4%)发生了移植后 HEV 感染。移植后 HEV 感染与移植物排斥的风险增加相关(比值比,14.2;P=0.03)。无个体发生慢性感染。
美国的实体器官移植受者存在移植后 HEV 感染的风险。需要进一步的研究来描述环境风险因素和北美 SOT 后 HEV 感染的风险。